P648: Clinical feasibility of dried blood sampling for infliximab in IBD patientsECCO '18 Vienna
2018
P650: Combination therapy for perianal fistulising Crohn’s disease in biological era: What is the optimal time for surgical intervention?ECCO '18 Vienna
2018
P651: Reliability of blood tests, neutrophil lymphocyte ratio (NLR) and Glasgow prognostic index (GPI) to evaluate the severity of the Crohn’s diseaseECCO '18 Vienna
2018
P652: Nutritional adequacy of popular defined diets for inflammatory bowel diseaseECCO '18 Vienna
2018
P653: Impact of ileostomy on recurrence rate after ileo-colic resection for Crohn’s disease: A critical appraisal from a referral centreECCO '18 Vienna
2018
P655: Immunogenicity after transition from adalimumab to ABP 501 in patients with plaque psoriasisECCO '18 Vienna
2018
P656: Are trough levels of anti-TNF drugs related with treatment failure and duration of treatment?ECCO '18 Vienna
2018
P657: Postoperative outcome in Crohn’s disease: Observational study of 1283 surgical patientsECCO '18 Vienna
2018
P658: Faecal calprotectin is capable of predicting mucosal healing in paediatric-onset Crohn’s disease patients under sustained clinical remission with biologicsECCO '18 Vienna
2018
P659: FMT as a treatment for IBD: A national survey of gastroenterologists in the UKECCO '18 Vienna
2018
P660: A pilot elastography study in patients with inflammatory bowel disease on long-term treatment with azathioprineECCO '18 Vienna
2018
P662: Transmural healing evaluated by magnetic resonance enterography in paediatric Crohn’s disease patients under maintenance treatment with biologicsECCO '18 Vienna
2018
P663: Primary prevention of post-operative recurrence of Crohn’s disease with anti-TNF agents in real life. Preliminary data from the Spanish ENEIDA registryECCO '18 Vienna
2018
P664: Association between pharmacologic loss of response profile of anti-TNF and clinical outcome with vedolizumabECCO '18 Vienna
2018
P665: Higher BMI but not systemic immune suppression increases the risk of short-term postoperative complications in Crohn’s disease patientsECCO '18 Vienna
2018
P666: Long-term effectiveness and safety of vedolizumab (VDZ) in inflammatory bowel disease (IBD): Results from the Spanish ENEIDA RegistryECCO '18 Vienna
2018